Treatment of NSCLC: Best Practices from the University of Kansas Cancer Center and Satellites : Episode 6
Approaches to Treatment and Staging in Unresectable NSCLC
Gregory Gan, MD, briefly outlines the available treatment strategies for stage III unresectable NSCLC, and Alykhan Nagji, MD explores the characterization of patients with unresectable stage III NSCLC, underscoring the crucial role of accurate staging in guiding treatment decisions.
EP: 1.Available Treatment Options for Patients With Stage-III Resectable NSCLC
EP: 2.Determining Eligibility for Surgical Resection in NSCLC
EP: 3.Expert Perspectives on Perioperative Immunotherapy in Resectable Stage-III NSCLC
EP: 4.Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting
EP: 5.Treatment Strategies for NSCLC Following Progression on Adjuvant Immunotherapy
Now Viewing
EP: 6.Approaches to Treatment and Staging in Unresectable NSCLC
EP: 7.Sequential and Concurrent Chemoradiotherapy in Unresectable Stage-III NSCLC
EP: 8.Expert Insights on Adjuvant Immunotherapy in Unresectable Stage-III NSCLC
EP: 9.Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations
EP: 10.The Potential Role of Combination Adjuvant Immunotherapy in NSCLC
EP: 11.Insights into Strategies Using Concurrent Immunotherapy with Chemoradiotherapy
EP: 12.Clinical Pearls for Treating NSCLC: Insights from Experts at the University of Kansas
EP: 13.Case 1: 72-Year-Old Former Smoker with Stage-IIIA NSCLC and PD-L1 of 90%
EP: 14.Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%
EP: 15.Case 3: 70-Year-Old Former Smoker with Stage IIIB NSCLC with PD-L1 10%
EP: 16.Case 4: 71-Year-Old Diagnosed with Stage IIIA NSCLC Experiencing Pneumonitis After Chemo-IO Treatment
EP: 17.A Multidisciplinary Approach to Treating Resectable NSCLC
Recent Videos
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
